1. Home
  2. CINGW vs EXEL Comparison

CINGW vs EXEL Comparison

Compare CINGW & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • EXEL
  • Stock Information
  • Founded
  • CINGW N/A
  • EXEL 1994
  • Country
  • CINGW United States
  • EXEL United States
  • Employees
  • CINGW 13
  • EXEL N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • EXEL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CINGW Health Care
  • EXEL Health Care
  • Exchange
  • CINGW Nasdaq
  • EXEL Nasdaq
  • Market Cap
  • CINGW N/A
  • EXEL N/A
  • IPO Year
  • CINGW 2021
  • EXEL 2000
  • Fundamental
  • Price
  • CINGW $0.04
  • EXEL $36.78
  • Analyst Decision
  • CINGW
  • EXEL Buy
  • Analyst Count
  • CINGW 0
  • EXEL 18
  • Target Price
  • CINGW N/A
  • EXEL $37.59
  • AVG Volume (30 Days)
  • CINGW N/A
  • EXEL 2.5M
  • Earning Date
  • CINGW N/A
  • EXEL 05-02-2025
  • Dividend Yield
  • CINGW N/A
  • EXEL N/A
  • EPS Growth
  • CINGW N/A
  • EXEL 170.77
  • EPS
  • CINGW N/A
  • EXEL 1.76
  • Revenue
  • CINGW N/A
  • EXEL $2,168,701,000.00
  • Revenue This Year
  • CINGW N/A
  • EXEL $5.82
  • Revenue Next Year
  • CINGW N/A
  • EXEL $10.81
  • P/E Ratio
  • CINGW N/A
  • EXEL $20.73
  • Revenue Growth
  • CINGW N/A
  • EXEL 18.50
  • 52 Week Low
  • CINGW N/A
  • EXEL $20.14
  • 52 Week High
  • CINGW N/A
  • EXEL $40.02
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • EXEL 54.16
  • Support Level
  • CINGW N/A
  • EXEL $35.34
  • Resistance Level
  • CINGW N/A
  • EXEL $36.56
  • Average True Range (ATR)
  • CINGW 0.00
  • EXEL 1.42
  • MACD
  • CINGW 0.00
  • EXEL 0.13
  • Stochastic Oscillator
  • CINGW 0.00
  • EXEL 83.18

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: